At AbbVie, Richard Gonzalez has 26 colleagues who can be contacted including Brett Hart (Director), Edward Rapp (Director)… Industry Colleagues. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience. The costs are hitting Medicaid programs extraordinarily hard [...], Just three months before its planned split into two companies, Abbott Laboratories is suffering a significant setback after a Phase III trial for a chronic kidney disease treatment was ended due to an excessive number of deaths and serious adverse events in patients. AbbVie estimates global sales of the drug at $1 billion in 2016 and $5 billion in 2020. In 2007, he retired after contracting throat cancer. He decided to make culture a key strategy. Richard Gonzalez is the chairman of the board and CEO of pharmaceutical company AbbVie. He was President and Chief Operating Officer before a two-year retirement. These Americans Are Rich - Should We Celebrate? Allergan owns the drug botox (ever heard of that?) Work hours are flexible with job sharing and strong support for parents with children. The Abbott board should investigated the confusion over the university degrees attributed to Richard Gonzalez, a long-standing Abbott exec who will soon head a spin off company called AbbVie. So what do you think he did? Companies that were once the source of fabulous wealth for Americans – the U.S. Steel profits that enriched the Carnegie family, the Ford Motor Company profits that enriched its eponymous family – are now struggling to keep up with foreign [...], A number of recent high-profile events in the pharmaceutical industry have showcased the significance of lead product dependency – that is, the proportion of revenues a company derives from its largest selling drug – on corporate strategy. He knew that innovation was the key to AbbVie’s future and that people were the key to innovation. Required fields are marked *. Your email address will not be published.

How Lead Product Dependency Shapes Corporate Strategy In Pharma, Abbvie To Pay $21 Billion For Cancer Biotech Pharmacyclics, At $1,000 A Pill, Hepatitis C Drug Sovaldi Rattles Medicaid Programs, For Abbott, Setbacks Happen In Threes; Now, A Kidney Drug Trial Ends Over Deaths, Abbott Board Should Probe Confusion Over Gonzalez Credentials, Amputation May Improve Abbott's Prognosis. There is even a formal phased retirement program where older staffs can help determine how to transition to retirement. Abbvie apparently beat out other companies, including Johnson & Johnson (JNJ) [...], Medicaid health insurance programs for the poor are grappling with how to pay for the costly Hepatitis C treatment Sovaldi, which costs $1,000 a pill and is running up a huge tab for states already grappling with myriad health and general budgetary issues. AbbVie is based in North Chicago and has child care on-site. All Rights Reserved. AbbVie Inc. researches and develops pharmaceutical products. The results can also be seen in the company’s innovation. CEO Richard Gonzalez has lifted the company onto a higher level of growth. Originally an executive vice president at Abbott Laboratories, he was asked to lead AbbVie, its spinoff company, when it was launched in 2013. Its current dividend yield is 5.3 percent. Not bad! Its EU patent expired in 2018, and its US patent expires in 2023. Prior to AbbVie’s separation from Abbott in January 2013, Mr. Gonzalez was a 30-year Abbott veteran. But cancer could not keep him down.

After splitting from Abbott Laboratories in January 2013, AbbVie’s future looked cloudy (ABBV: NYSE). “Ultimately, we want everyone to feel like AbbVie is a place where they belong, do great, and can grow their career.”. They have already grabbed some in-play market share. The for-sale signs could start hanging over Westfield’s U.S. shopping malls after next week, as a multi-billion-dollar fight over the future of the shopping center giant gets played out at a potentially explosive shareholder meeting. - Abbott Chief Miles White Abbott Laboratories announced plans this morning to split itself in two, spinning off its $18 billion pharmaceuticals arm under a new name.

(AP Photo/Pablo Martinez Monsivais)